549 related articles for article (PubMed ID: 19136675)
1. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
[TBL] [Abstract][Full Text] [Related]
2. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.
Kügler M; Stein C; Schwenkert M; Saul D; Vockentanz L; Huber T; Wetzel SK; Scholz O; Plückthun A; Honegger A; Fey GH
Protein Eng Des Sel; 2009 Mar; 22(3):135-47. PubMed ID: 19188138
[TBL] [Abstract][Full Text] [Related]
3. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains.
Jung S; Spinelli S; Schimmele B; Honegger A; Pugliese L; Cambillau C; Plückthun A
J Mol Biol; 2001 Jun; 309(3):701-16. PubMed ID: 11397090
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold.
Jespers L; Schon O; James LC; Veprintsev D; Winter G
J Mol Biol; 2004 Apr; 337(4):893-903. PubMed ID: 15033359
[TBL] [Abstract][Full Text] [Related]
5. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.
Ewert S; Honegger A; Plückthun A
Biochemistry; 2003 Feb; 42(6):1517-28. PubMed ID: 12578364
[TBL] [Abstract][Full Text] [Related]
6. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
7. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.
Tanha J; Nguyen TD; Ng A; Ryan S; Ni F; Mackenzie R
Protein Eng Des Sel; 2006 Nov; 19(11):503-9. PubMed ID: 16971398
[TBL] [Abstract][Full Text] [Related]
8. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
9. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding.
Proba K; Honegger A; Plückthun A
J Mol Biol; 1997 Jan; 265(2):161-72. PubMed ID: 9020980
[TBL] [Abstract][Full Text] [Related]
10. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies.
Pedersen JT; Henry AH; Searle SJ; Guild BC; Roguska M; Rees AR
J Mol Biol; 1994 Jan; 235(3):959-73. PubMed ID: 7507176
[TBL] [Abstract][Full Text] [Related]
11. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points.
Arbabi-Ghahroudi M; To R; Gaudette N; Hirama T; Ding W; MacKenzie R; Tanha J
Protein Eng Des Sel; 2009 Feb; 22(2):59-66. PubMed ID: 19033278
[TBL] [Abstract][Full Text] [Related]
12. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.
Wörn A; Plückthun A
Biochemistry; 1998 Sep; 37(38):13120-7. PubMed ID: 9748318
[TBL] [Abstract][Full Text] [Related]
13. Intrabody construction and expression. II. A synthetic catalytic Fv fragment.
Ohage EC; Wirtz P; Barnikow J; Steipe B
J Mol Biol; 1999 Sep; 291(5):1129-34. PubMed ID: 10518948
[TBL] [Abstract][Full Text] [Related]
14. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
15. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.
Xiang J; Sha Y; Jia Z; Prasad L; Delbaere LT
J Mol Biol; 1995 Oct; 253(3):385-90. PubMed ID: 7473721
[TBL] [Abstract][Full Text] [Related]
16. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
17. Intrabody construction and expression III: engineering hyperstable V(H) domains.
Wirtz P; Steipe B
Protein Sci; 1999 Nov; 8(11):2245-50. PubMed ID: 10595527
[TBL] [Abstract][Full Text] [Related]
18. Antibody scFv fragments without disulfide bonds made by molecular evolution.
Proba K; Wörn A; Honegger A; Plückthun A
J Mol Biol; 1998 Jan; 275(2):245-53. PubMed ID: 9466907
[TBL] [Abstract][Full Text] [Related]
19. DNA binding by the VH domain of anti-Z-DNA antibody and its modulation by association of the VL domain.
Chen Y; Stollar BD
J Immunol; 1999 Apr; 162(8):4663-70. PubMed ID: 10202006
[TBL] [Abstract][Full Text] [Related]
20. Biophysical properties of human antibody variable domains.
Ewert S; Huber T; Honegger A; Plückthun A
J Mol Biol; 2003 Jan; 325(3):531-53. PubMed ID: 12498801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
